FindTrial
Sign In

Pharmacogenomics research of Metformin in Gastrointestinal (MIGI) Side effects

Pharmacogenomics research of Metformin in Gastrointestinal (MIGI) Side effects

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOD-17011700
Enrollment
Unknown
Registered
2017-06-19
Start date
2017-08-01
Completion date
Unknown
Last updated
2017-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Interventions

1:metformin by different doses

Sponsors

Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 20-70 years old, man or woman; 2. 20 = BMI = 35 kg/m2; 3. 7%=HbA1c=10.0%; 4. creatinine clearance rate> 60 ml/min/1.73m2 5. medication-naive type 2 diabetes with newly-onset;

Exclusion criteria

Exclusion criteria: 1. type 1 diabetes, 2. gestational diabetes 3. special type of diabetes 4. women with pregnancy, lactation or without effective conception; 5. with the disease or treatment affecting the effect of safety of metformin, including hypoxia, hepatic dysfunction, renal dysfuntion, coronary heart disease, etc. 6. with mental disease. 7. endangering the safety of subjects, or influencing compliance. 8. with medication influencing on glucose metabolism including glucocorticoid, thyroxine, thiazide diuretics 9. with acute complications or infection 10. with long-term diarrhea, anemia.

Design outcomes

Primary

MeasureTime frame
pharmacogenomics;Gut microbiota;—

Secondary

MeasureTime frame
prevelance of gastrointestinal side effects;—

Countries

China

Contacts

Public ContactJIA WEIPING

Shanghai Sixth People's Hospital

wpjia@sjtu.edu.cn+86 13818888939

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026